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Abstract
Introduction: More than 90% of patients with pancreatic cancer present either with incurable locally advanced or metastatic disease or
relapse following surgery. For these patients systemic therapy offers the only prospect of salvage, but pancreatic cancer is one of the
most chemoresistant of tumors; current chemotherapy can only delay progression in a limited proportion of patients and survival rates
are poor. There is therefore a pressing need for more effective therapy. Capecitabine is a new oral prodrug of fluorouracil, which has
shown activity in pancreatic cancer particularly when used in combination with gemcitabine.
Aims: To review the emerging evidence for the clinical effectiveness of capecitabine in the management of carcinoma of the pancreas.
Evidence review: There is evidence from phase II testing that capecitabine is active in pancreatic cancer. The Swiss Group for Clinical
Cancer Research/Central European Cooperative Oncology Group (SAKK/CECOG) phase III trial found that the combination of
gemcitabine and capecitabine did not improve overall median survival as compared with gemcitabine alone (8.4 vs 7.3 months,
respectively; P=0.314) but subgroup analysis in patients with good performance score [Karnofsky Performance Scores (KPS) ≥90]
revealed a significant survival improvement with the combination arm (10.1 months) compared with single-agent gemcitabine 
(7.5 months; P=0.033). Preliminary data from the GemCap phase III trial indicated significantly improved response rates and survival for
the combination of gemcitabine with capecitabine (7.4 months) compared with gemcitabine alone (6 months; P=0.026) but analysis of
the mature data with adequate follow-up awaits reporting.
Clinical potential: The addition of capecitabine to gemcitabine may represent a small step forward in the management of advanced
pancreatic cancer but further data are required in order to determine its full impact.
Core Evidence. 2007;2(2):111–119.
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Core evidence outcomes summary for capecitabine in advanced carcinoma of the pancreas
Outcome measure Evidence Implications
Patient-oriented evidence
Statistically significant improvement in survival in combination
with gemcitabine
Substantial Capecitabine can be considered as first-line treatment in combination with
gemcitabine to prolong survival by a small but significant margin
Clinical benefit in good PS patients Moderate Patients with good PS more likely to benefit from combination chemotherapy
Acceptable toxicity profile Substantial The addition of capecitabine is generally well tolerated
Disease-oriented evidence
Statistically significant response rate improvement in
combination with gemcitabine
Substantial Capecitabine can be administered as first-line treatment in combination with
gemcitabine to improve response rates
Economic evidence
Capecitabine adds only drug-acquisition costs to 
gemcitabine therapy
Substantial Minor additional resource implications
PS, performance status.Scope, aims, and objectives
Capecitabine (Xeloda®, F. Hoffmann-La Roche) is an orally active
prodrug of the fluoropyrimidine fluorouracil (Miwa et al. 1998;
Tabata et al. 2004). This review seeks to assess the emerging
evidence for capecitabine in the management of carcinoma of 
the pancreas. 
Methods
English language literature searches were conducted on
September 25, 2006 in the following databases, searching from
the beginning of the database to current date unless otherwise
stated. The search strategy was “capecitabine AND pancreatic
cancer” unless otherwise stated:
• PubMed, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi, 1966
to date. Limits imposed for specificity: “English,” 
“clinical trial,” “meta analysis,” “randomized controlled 
trial,” “humans” 
• EMBASE, http://www.datastarweb.com
• BIOSIS, http://www.datastarweb.com 
• Database of Abstracts of Reviews of Effects (DARE), National
Health Service (NHS) Economic Evaluations Database
(NHSEED), Health Technology Assessment (HTA),
http://www.york.ac.uk/inst/crd/crddatabases.htm. All three
databases searched together. All fields searched
• NHS HTA, http://www.ncchta.org
• National Guideline Clearinghouse, http://www.guideline.gov
• National Institute for Health and Clinical Excellence (NICE),
http://www.nice.org.uk
• Cochrane Database of Systematic Reviews (CDSR),
http://www.cochrane.org/index0.htm. Entire site searched
• Clinical Evidence (BMJ), http://www.clinicalevidence.com
Online abstracts from the following congresses were searched
using the search term “capecitabine”:
• American Society of Clinical Oncology, all conferences from
2000 to 2006, http://www.asco.org 
• European Society for Medical Oncology, all conferences from
2003 to 2005, http://www.esmo.org
• European Cancer Conference 2005,
http://ex2.excerptamedica.com/ciw-05ecco
Following hand searching and removal of duplicates,
nonsystematic reviews, editorials, records of study methodology,
and pharmacokinetic studies, a total of nine full papers and 
16 abstracts were included in the evidence base.
After peer review of the initial submission there was a further
search of the abstracts presented at the joint meeting of the
International Association of Pancreatology and the American
Association of Pancreatology meeting held in November 2006.
This identified a further systematic review and meta analysis
(Sultana et al. 2006). An additional phase II trial was identified via
PubMed published in March 2007 (Park et al. 2007). Since the
literature searches were conducted, the study by Moore and
colleagues has been published as a full paper (Moore et al. 2007).
A summary of the literature search results is shown in Table 1. 
Disease overview 
Adenocarcinoma of the pancreas is one of the main causes of
cancer-related death in the western world with about 33 000 new
cases annually in the USA (Jemal et al. 2007) and 7000 in the UK
(Office for National Statistics 2005). Pancreatic cancer is more
common in men (male:female ratio 1.3:1) and is unusual before
the age of 45 years but the incidence rises sharply thereafter,
reaching a peak in the mid to late 70s. The majority of cases have
no obvious genetic predisposition but 5–10% of patients have a
first-degree relative with the disease, suggesting some form of
familial aggregation (McWilliams et al. 2005; McFaul et al. 2006).
The risk of developing pancreatic cancer is increased in a number
of familial cancer syndromes (Vitone et al. 2006); for example, the
lifetime risk in Peutz-Jegher syndrome approaches 36%
(Giardiello et al. 2000; Latchford et al. 2006). Patients with
hereditary pancreatitis have a 40% chance of developing
pancreatic cancer by the age of 70 (Howes et al. 2004) but the risk
is lower for sporadic forms of chronic pancreatitis (Howes &
Neoptolemos 2002). Several environmental and lifestyle factors
have been implicated in the development of pancreatic cancer
including smoking, diet, and body mass index (Vimalachandran et
al. 2004). Of these the evidence is most conclusive for cigarette
smoking with a two-fold increased risk (Coughlin et al. 2000).
The majority of patients present with painless obstructive
jaundice, although upper abdominal and/or back pain, anorexia,
and weight loss are also common (Alexakis et al. 2004). Initial
investigations include routine hematology, biochemistry,
computed tomography scanning of the chest and abdomen, and
serum carcinoembryonic (CA) 19-9 estimation, a tumor marker
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Category Number of records
Full papers Abstracts
Initial search 10 102
records excluded 1 86
records included 9 16
Additional studies identified 0 1
Total records included 9 17
Level 1 clinical evidence  0 1
Level 2 clinical evidence  1 4
Level ≥3 clinical evidence
trials other than RCT 8 11
case reports 0 1
Economic evidence 0 0
For definitions of levels of evidence, see Editorial Information on inside back cover.
RCT, randomized controlled trial.
Table 1 | Evidence base included in the review113
detectable in a high proportion of patients with pancreatic cancer
(BSG 2005). Surgical resection remains the only potentially
curative treatment; however, the majority of patients have either
locally advanced or metastatic disease at presentation and only
around 10% of patients are candidates for pancreatectomy
(Alexakis et al. 2004). The prognosis for patients with pancreatic
cancer is poor with an overall survival of 0.4%, median survival of
8 to 12 months for patients with locally advanced disease, and 3
to 6 months for those who present with metastases (Bramhall et
al. 1995). For patients with resectable disease the 5-year survival
is around 10% for patients with node-positive disease, and
20–30% for those with node-negative cancers (Alexakis et 
al. 2004). 
Current therapy options
Adenocarcinoma of the pancreas is highly resistant to
radiotherapy and chemotherapy (Sultana et al. 2006, 2007; Yip et
al. 2006) and although many drugs have been tested in this
disease none have consistently demonstrated objective response
rates above 10% (Shore et al. 2003). Pancreatic cancer has a
highly complex molecular pathology and is uniquely characterized
by a high frequency of activating K-ras mutations and loss of
function of the p53, p16, and Smad 4 tumor suppresser genes
(Bardeesy & DePinho 2002). A number of altered signaling, DNA
repair, and apoptotis pathways may contribute to the resistance
of pancreatic cancer to conventional therapies, notably block of
the p16/pRb cell cycle control system (Plath et al. 2002). The
phosphoinositide 3-OH kinase (PI3K)/Akt pathway, which is
frequently amplified or activated in pancreatic cancer, may also
contribute to resistance in several ways including the inhibition of
proapoptotic proteins BAD and caspase 9 (Schlieman et al. 2003),
dysregulation of the mammalian target of rapamycin (mTOR)-
S6K1 signaling pathway (Asano et al. 2005), and activation of the
nuclear factor kappa B (NFκB) transcription factor (Fernandez-
Zapico & Urrutia 2004).
The fluoropyrimidine fluorouracil is used extensively in the
treatment of a number of gastrointestinal malignancies including
esophageal, gastric, and colorectal cancers, and historically
––before the introduction of gemcitabine––was considered to be
the most effective available treatment for advanced pancreatic
cancer (Carter & Comis 1975; Shore et al. 2003). However, more
recent trials of fluorouracil with folinic acid (leucovorin) modulation
using both infusional and bolus schedules suggest a relatively low
response range (0–9%) and a median survival of 10–24 weeks
(Crown et al. 1991; Decaprio et al. 1991; Shore et al. 2003; Van
Rijswijk et al. 2004). The deoxycytidine analog gemcitabine has
now replaced fluorouracil as the treatment of choice for advanced
pancreatic cancer (Burris et al. 1997) with slightly improved
objective response rates (6–11%) in chemotherapy-naïve patients
(Casper et al. 1994; Carmichael et al. 1996) but with superior
clinical benefit response (Burris et al. 1997). Clinical benefit
response was initially defined in a phase II study of gemcitabine
as an improvement in pain (analgesic consumption and pain
intensity), Karnofsky Performance Scores (KPS), or weight gain
without a deterioration in any other factor even in the absence of
an objective response (Rothenberg et al. 1996). In this trial
although the objective response rate for patients with measurable
disease was only 11%, a clinical benefit was observed in 27%. 
In the pivotal trial by Burris et al. (1997) both clinical benefit and
survival were used as the primary endpoints, where clinical
benefit required a sustained (≥4 weeks) improvement in at least
one parameter without worsening in any others. One hundred and
twenty-six previously untreated patients with locally advanced or
metastatic pancreatic cancer were randomized between
fluorouracil (600 mg/m2 intravenous bolus weekly) or gemcitabine
(1000 mg/m2 intravenous infusion weekly for 7 weeks followed by
a week of rest, then weekly for 3 out of every 4 weeks). Of 
56 patients in the gemcitabine arm with bidimensionally
measurable disease at study entry, three (5.4%) had a partial
response and 22 (39%) had stable disease. Among 
57 fluorouracil-treated patients with measurable disease, none
had a complete or partial response and 11 (19%) had stable
disease. The difference in partial response rates was not
statistically significant. Despite the fact that there was no
difference in objective response rate between the two groups,
gemcitabine was associated with significantly better clinical
benefit response (24%) compared with fluorouracil (5%;
P=0.002). The median survival was 5.7 months for gemcitabine-
treated patients and 4.4 months for the fluorouracil-treated
patients, with 1-year survival rates of 18% versus 2%,
respectively (P=0.0025). Criticisms of this study included failure to
use a prospectively validated quality-of-life instrument, not using
blind treatment assignment for those assessing clinical benefit
responses, and comparison with a control arm which employed
what is now considered to be a suboptimal method of delivering
fluorouracil. Nevertheless, gemcitabine was approved for first-line
therapy of metastatic pancreatic cancer and, given its relatively
low toxicity, it is now the drug of choice (Shore et al. 2003).
In the adjuvant setting both fluorouracil/leucovorin and single-
agent gemcitabine each have been tested in two separate 
phase III trials called ESPAC-1 and CONKO-001, respectively
(Neoptolemos et al. 2004; Ghaneh et al. 2006; Oettle et al. 2007).
Although both regimens produced a similar doubling in 5-year
survival rates compared with the control (resection-only) arms, in
the case of CONKO-001 the primary endpoint was progression-
free survival rather than overall survival as in ESPAC-1
(Neoptolemos et al. 2004; Ghaneh et al. 2006; Oettle et al. 2007).
A number of groups have investigated other, newer drugs in
advanced pancreatic cancer both as single agents and in
combination. Studies involving anthracyclines, ifosfamide,
taxanes, camptothecins, and platinum analogs have all yielded
response rates of less than 10% with no demonstrable
improvement in overall survival (Shore et al. 2003). Many
combinations have also been tested and although a number of
phase II trials have suggested improved response rates for
combination chemotherapy, up to now there has been little
evidence that these are translated into improved survival (Yip et
al. 2006). A systematic review and meta analysis has also
demonstrated that chemoradiation followed by chemotherapy
does not demonstrate any survival advantage over chemotherapy
alone (Sultana et al. 2007).
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agent gemcitabine remained the standard of care (Yip et al. 2006),
a more up to date meta analysis indicated that gemcitabine
combined with a platinum derivative was indeed superior to
gemcitabine alone (Sultana et al. 2006).
Moreover, erlotinib, a small molecule tyrosine kinase inhibitor, has
also recently been shown to have limited clinical benefit in
combination with gemcitabine in the National Canadian Institute
of Cancer-led international, multicenter, placebo-controlled 
phase III trial (PA.3) (Moore et al. 2005). Approximately 75% of the
569 patients randomized had metastatic disease. The overall
survival was significantly better in the erlotinib arm compared with
the placebo-controlled arm with a median survival of 6.4 versus
5.9 months [hazard ratio (HR) 0.81; 95% confidence intervals (CI)
0.67, 0.97; P=0.025] and a 1-year survival of 24% versus 17%,
respectively. Progression-free survival was also significantly
improved with medians of 3.8 versus 3.6 months, respectively
(HR 0.76; 95% CI 0.63, 0.91; P=0.003). The overall response rate,
however, was not different between the two arms (8.6% vs 8.0%,
respectively). Toxicity from skin rash and diarrhea was increased
in the erlotinib arm although there were no significant differences
for global quality-of-life scores (Moore et al. 2005). 
In July 2006, the Committee for Medicinal Products for Human
Use (CHMP) representing the European Medicines Agency
(EMEA) rejected registration of erlotinib because the survival
benefit of the combination was very limited. It was concluded that
the benefit did not outweigh the risk of side effects, and there was
neither improvement in the quality of life nor in progression-free
survival and objective response rate (EMEA 2006). In December
2006, however, the CHMP recommended the granting of a
variation to the marketing authorization for erlotinib for patients
with metastatic cancer based on the evidence that there was a
25% improvement in overall survival in this group of patients (but
not in patients with locally advanced disease). The Committee
also concluded that erlotinib could be prescribed on a 
patient-by-patient basis, taking into account the chance of
survival (EMEA 2006).
Unmet needs
The majority of patients with pancreatic cancer will either present
with inoperable or metastatic disease or will relapse following
resection leading to an overall 5-year survival of <5% (Alexakis et
al. 2004). Despite the progress made with gemcitabine, systemic
therapy is of limited value, with only a small percentage of
patients experiencing a short-term benefit usually lasting 
4 months or less and the 1-year survival in this group is around
18–20% (Burris et al. 1997). Although there may be improved
survival with the combinations of gemcitabine with either erlotinib
(Moore et al. 2005) or a platinum derivative (Sultana et al. 2006),
the absolute improvement in survival is small. The 5-year survival
rate following resection alone is about 10%, improving to around
23–29% with adjuvant systemic chemotherapy with either
fluorouracil and leucovorin or gemcitabine but most patients
relapse soon after (Neoptolemos et al. 2004; Ghaneh et al. 2006;
Oettle et al. 2007). There is therefore an urgent need for new
effective treatments to use in this disease both in locally
advanced disease and as adjuvant therapy following potentially
curative resection.
Clinical evidence with capecitabine in advanced
carcinoma of the pancreas
Fluorouracil is most active and least toxic when delivered using an
infusional schedule (Meta-analysis Group In Cancer 1998) but
such treatment either involves a prolonged inpatient stay or the
placement of a central line with its attendant risks and
inconvenience. Continuous oral dosing can be used to mimic a
protracted infusion but this is not possible with fluorouracil
because extensive metabolism by dihydropyrimidine
dehydrogenase in the mucosa of the gastrointestinal tract and the
liver leads to highly variable bioavailability (Schoffski 2004; Tabata
et al. 2004). 
Capecitabine is a fluorouracil prodrug which was developed in an
effort to overcome this problem (Miwa et al. 1998). It is absorbed
intact through the intestinal wall unaffected by dihydropyrimidine
dehydrogenase and then undergoes conversion to fluorouracil in
a sequential three-stage enzymatic process (Miwa et al. 1998).
The final requisite enzyme, thymidine phosphorylase, is present at
consistently higher levels in tumor compared with normal tissues,
thereby suggesting that fluorouracil delivered in this way may
benefit from an element of tumor targeting and thus enhanced
selectivity and better tolerability (Ishikawa et al. 1998). Clinical
evidence to support this comes from a study in patients with
colorectal cancer. Capecitabine was administered 7 days before
planned resection of the primary cancer and fluorouracil levels
assayed in tumor and adjacent tissues. The median ratio of
fluorouracil concentration in colorectal tumors to adjacent tissues
was 2.9 (range 0.9–8.0) (Schüller et al. 2000). The effectiveness of
capecitabine is such that it may replace fluorouracil as the
fluoropyrimidine of choice in colorectal (Van Cutsem et al. 2001;
Twelves et al. 2005) and perhaps other cancers as well.
Efficacy
An initial phase II trial of 42 patients with locally advanced or
metastatic pancreatic cancer who had received no prior
chemotherapy, were treated with standard capecitabine
monotherapy (1250 mg/m2 twice daily on days 1–14 of a 3-week
cycle) in order to investigate safety and efficacy (Cartwright et al.
2002). The major grade 3/4 adverse events were diarrhea, hand-
foot syndrome, and nausea, and overall the safety profile was
similar to that of capecitabine in patients with colorectal and
breast cancer. Ten (24%) patients achieved a clinical benefit
response and 12 (29%) patients had reduced pain intensity. The
overall median survival was 6 months with three (7%) partial
responses and another 17 (41%) patients with stable disease for
a median duration of 2.8 months. 
Capecitabine appeared to have definite, albeit limited, activity in
advanced pancreatic cancer and it was therefore decided to
explore combination treatment with gemcitabine as the next
phase of development. This was based on potential synergy
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between gemcitabine and capecitabine as a result of gemcitabine
inhibiting ribonucleotide reductase thus depleting intracellular
pools of deoxyuridine monophosphate and leading to enhanced
binding of 5-fluorodeoxyuridine monophosphate, the active
metabolite of fluorouracil, to thymidylate synthase (Ren et al.
1998) (Fig. 1). 
Phase I/II dose-finding trials were conducted using both 21- and
28-day cycles. An initial study investigated capecitabine in
combination with gemcitabine in 36 patients with previously
untreated pancreatic cancer (Hess et al. 2003). Escalating doses
of capecitabine were administered keeping gemcitabine at a fixed
dose of 1000 mg/m2 on days 1 and 8. The dose-limiting toxicities
were neutropenia and mucositis. A 21-day regimen of
capecitabine 650 mg/m2 twice daily on days 1–14 in combination
with gemcitabine 1000 mg/m2 on days 1 and 8 was found to be
the most suitable regimen for phase II testing. There was only one
grade 4 adverse event in the 12 patients treated at this dose level
and there were no cases of diarrhea, hand-foot syndrome, or
alopecia in these patients. In patients with evaluable disease the
overall response rate was 15%. A second phase I trial in patients
with advanced pancreatic cancer determined that capecitabine
880 mg/m2 twice daily on days 1–21 of a 28-day cycle with
gemcitabine 1000 mg/m2 on days 1, 8, and 15 was the most
appropriate regimen for further investigation (Schilsky et al. 2002). 
A subsequent phase II trial using a 21-day schedule of
gemcitabine 1000 mg/m2 on days 1 and 8 plus capecitabine 
650 mg/m2 on days 1–14 involved 53 patients with advanced
pancreatic cancer. There were 10 (18%) partial remissions, 
22 patients (42%) with stable disease, and 15 (28%) with
progressive disease (Stathopoulos et al. 2004). The median time
to progression was 6 months, the median survival was 8 months,
and 12-month survival was 35%. 
Similar results have been reported recently from Korea in a 
phase II study of 45 patients with advanced pancreatic cancer
given gemcitabine combined with dose-escalated 14-day
capecitabine as first-line chemotherapy (Park et al. 2007).
Gemcitabine 1000 mg/m2 was given on days 1 and 8 plus
capecitabine 1000 mg/m2 twice daily on days 1–14, in 21-day
cycles. The objective response rate was 40% (95% CI 25%,
55%), including one (2%) complete response. The median time to
progression was 5.4 months (95% CI 1.8, 9.0) and the median
overall survival was 10.4 months (95% CI 6.2, 14.5). Patients with
a ≥25% decline of serum CA19-9 had significantly better time to
progression and overall survival than those who did not (P<0.03).
The most frequent nonhematologic grade 3/4 toxicity was hand-
foot syndrome (7%) (Park et al. 2007).
Following on from the earlier phase I/II studies, the combination
of gemcitabine with capecitabine has been compared with
gemcitabine alone in one randomized phase II (Scheithauer et al.
2003a) and two phase III trials (Cunningham et al. 2005; Herrmann
et al. 2005) and also in a randomized phase II trial against
gemcitabine plus oxaliplatin (GemOx) and capecitabine plus
oxaliplatin (XelOx) (Heinemann et al. 2005). 
In the initial randomized phase II study, 83 patients with
metastatic pancreatic cancer received either gemcitabine 
2200 mg/m2 intravenously alone on day 1 with or without
capecitabine 2500 mg/m2 per day orally on days 1–7 of a 14-day
cycle (Scheithauer et al. 2003a). The objective response rate for 
single-agent gemcitabine was 14% compared with 17% 
for the combination with capecitabine, with median 
survivals of 8.2 and 9.2 months, respectively. The clinical benefit
response was 33% for single-agent gemcitabine and 48% 
for the combination of gemcitabine with capecitabine. 
Overall these results support phase III investigation of
gemcitabine/capecitabine doublet regimens. 
The Swiss Group for Clinical Cancer Research (SAKK) jointly
performed a phase III trial with the Central European Cooperative
Oncology Group (CECOG) in 319 patients with pancreatic cancer,
of whom 79% had metastatic disease (Herrmann et al. 2005). In
the single-agent arm patients were randomized to gemcitabine
1000 mg/m2 intravenously on days 1 and 8; patients in the
combination arm were randomized to gemcitabine 1000 mg/m2
intravenously per week for 2 out of every 3 weeks and
capecitabine 1300 mg/m2 per day for the first 14 consecutive
days every 3 weeks. The median overall survival was 7.3 months
for gemcitabine and 8.4 months for the combination arm
(P=0.314) thus failing to reach the primary endpoint. The response
rate was 7.9% for single-agent gemcitabine and 10.1% for the
combination arm with a median duration of response of 
5.9 versus 7.4 months, respectively. The median time to
progression was 4 months for single-agent gemcitabine and 
4.8 months for the combination arm. There were 232 patients who
were at least 4 weeks on study treatment and therefore evaluable
for clinical benefit, of whom 111 (73%) had the combination and
121 (82%) had gemcitabine alone. Overall, 27 (18%) patients with
gemcitabine and capecitabine and 29 (20%) patients with 
single-agent gemcitabine had a clinical benefit response 
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Fig. 1 | Mechanism of action of capecitabine plus gemcitabine.
5-DFCR, 5-deoxyfluorocytidine; 5-DFUR, 
5-deoxyfluorouridine; 5-FdUMP, 5-fluorodeoxyuridine
monophosphate; DUMP, deoxyuridine monophosphate;
DTMP, deoxythymidine monophosphate; 
RNR, ribonucleotide reductase; TS, thymidylate synthaseand toxicity was low in both groups (Herrmann et al. 2005). 
Cox multivariate analysis found that patients with KPS ≥90 
had an improved median survival when treated with the
combination arm (10.1 months) compared with single-agent
gemcitabine (7.5 months; P=0.033) (Herrmann et al. 2005).
The second phase III trial (GemCap) was organized by the
National Cancer Research Institute and Cancer Research UK,
with a total of 533 patients randomized to gemcitabine (n=266) or
the combination of gemcitabine and capecitabine (n=267)
(Cunningham et al. 2005). Baseline characteristics were well
balanced between the gemcitabine and the combination arms
(Table 2). Patients randomized to the single-agent arm were
scheduled gemcitabine 1000 mg/m2 weekly for 7 out every 
8 weeks, then 1 week’s rest and thereafter weekly for the first 3 of
every 4 weeks. The schedule for the combination arm was
gemcitabine 1000 mg/m2 weekly for the first 3 of every 4 weeks;
capecitabine was given at a dose of 1660 mg/m2 per day orally
for 21 days every 4 weeks followed by 7 days’ rest. 
Preliminary results were reported following an interim analysis in
May 2005, when 373 (70%) deaths had occurred. Grade 3/4
toxicity episodes in the gemcitabine alone and combination arms
were anemia (2% vs 1%), neutropenia (11% vs 17%),
thrombocytopenia (2% vs 3%), fever (1% vs 0%), diarrhea (1% in
both groups), hand-foot syndrome (0% vs 2%), and vomiting 
(2% vs 1%). In the preliminary analysis grade 3/4 stomatitis had
not been reported in either group of patients. The objective
response rates were 7% (0 complete responses, 19 partial
responses) for gemcitabine alone and 14% (three complete
responses, 35 partial responses) for the combination arm
(P=0.008). Patients randomized to the combination arm had
improved overall survival compared with single-agent
gemcitabine (HR 0.80; 95% CI 0.65, 0.98; P=0.026). The median
survival was 6 months for patients receiving gemcitabine alone
compared with 7.4 months in the combination arm with 1-year
survival rates of 19% and 26%, respectively. After adjusting for
baseline stratification factors (stage of disease and performance
status), the survival advantage for the patients in the combination
arm remained (HR 0.77; 95%CI 0.63, 0.95; P=0.014). 
A further randomized, phase II study compared capecitabine plus
gemcitabine (n=50) with gemcitabine plus oxaliplatin (n=57) and
capecitabine plus oxaliplatin (n=54) (Heinemann et al. 2005). This
also showed a trend in favor of the capecitabine-containing arms
in terms of response rate and progression-free survival as follows.
Patients received 3-week regimens of either capecitabine 
2 x 1000 mg/m2 daily for 2 weeks plus oxaliplatin 130 mg/m2
intravenously on day 1 (CapOx); or capecitabine 2 x 825 mg/m2
daily for 2 weeks plus gemcitabine 1000 mg/m2 intravenously
weekly for 2 weeks (CapGem); or gemcitabine 1000 mg/m2
intravenously per week for 2 weeks plus oxaliplatin 130 mg/m2 on
day 8 (GemOx). Patients in the CapOx, CapGem, and GemOx
arms were well balanced with respect to KPS >70% (89% vs 92%
vs 90%, respectively) and stage of disease (metastatic 
disease in 74% vs 76% vs 75%, respectively). The overall 
median age was 63 years (range 37–75) and patients received a
median of four cycles of treatment. Hematologic grade 3/4
toxicity occurred in 6%, 16%, and 19% for the CapOx vs
CapGem vs GemOx groups, respectively; grade 3–4
neurosensoric toxicity was observed in 7%, 0%, and 
4%, respectively; while grade 2–3 hand-foot syndrome was 
found in 9%, 6%, and 2%, respectively. In October 2004, 
141 patients were evaluable for response. There were no
complete remissions; partial responses were obtained in 22%,
16%, and 13% of the CapOx vs CapGem vs GemOx groups,
respectively; and stable disease was reported in 33%, 45%, and
30% respectively. The disease control rates were therefore 55%,
61%, and 43% for the CapOx vs CapGem vs GemOx groups,
respectively. The median overall survival for CapOx was 243 days,
for CapGem was 229 days, and for GemOx was 241 days (P=0.6).
The median progression-free survival was 127 days, 143 days,
and 91 days for the CapOx vs CapGem vs GemOx groups,
respectively (Heinemann et al. 2005).
Although the SAKK/CECOG trial did not achieve statistical
significance for survival, it used a less dose-intense schedule of
the gemcitabine/capecitabine combination compared with the UK
GemCap trial and it was also comparatively underpowered.
Nevertheless, both trials demonstrated similar trends towards
improvements in overall survival and response rates. A recent
meta analysis has confirmed that the combination of gemcitabine
and capecitabine may be superior to single-agent gemcitabine
(Sultana et al. 2006). Overall, therefore, these preliminary data
suggest that the addition of capecitabine to gemcitabine results
in a small advantage particularly for patients with good
performance status.
There are limited data on second-line chemotherapy in pancreatic
cancer and none investigating capecitabine alone following
gemcitabine failure. However, the combination of capecitabine
plus oxaliplatin has been examined in this group of patients.
Oxaliplatin 130 mg/m2 on day 1 plus capecitabine 1000 mg/m2
twice daily on days 1–14 were administered on a 21-day schedule
to 41 patients who had progressed following gemcitabine (Xiong
et al. 2006). There was one partial response and eight patients
with stable disease, with a median survival of 5.8 months and 
12-month survival rate of 22%, suggesting at least some activity
in this difficult group of patients. 
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Gemcitabine Gemcitabine +
capecitabine
Patients 266 267
Median age (years) 62 62
Stage
metastatic (%) 71 70
locally advanced (%) 29 30
Performance status 0–1 (%) 82 81
Response rate (%) 7 14*
Median survival (months) 6.0 7.4
1-year survival (%) 19 26
*P=0.026.
Table 2 | National Cancer Research Institute/Cancer Research
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Capecitabine has also been included in studies of
chemoradiotherapy in locally advanced carcinoma of the
pancreas as an alternative to intravenous fluorouracil and has
been shown to be tolerable with predictable toxicity (Ben-Josef et
al. 2004; Crane et al. 2006). This is a somewhat of a controversial
area, however, with little evidence to suggest that chemoradiation
adds to systemic chemotherapy in this situation and additional
trials are required to define its role (Yip et al. 2006; Sultana 
et al. 2007).
Tolerability
The toxicity of capecitabine itself is relatively noncytotoxic in vivo
and thus the toxicity profile tends to reflect that of its active
metabolite fluorouracil (Van Cutsem et al. 2001, 2004;
Scheithauer et al. 2003b; Twelves et al. 2005). The toxicity of
fluorouracil is dependent on the schedule used. Whereas bolus
fluorouracil causes mainly diarrhea, oral mucositis,
myelosuppression, and ocular irritation, infusional fluorouracil
schedules tend to cause hand-foot syndrome and mucositis,
typically comprising inner lip surface ulcers, whereas significant
myelosuppression is unusual. The toxicity profile of capecitabine
appears to lie somewhere between that of bolus and infusional
fluorouracil (Budman et al. 1998) with up to 50% of patients
experiencing diarrhea of varying degrees that occasionally may
require hospital admission (Scheithauer et al 2003b; Twelves et al
2005). Hand-foot syndrome may occur in around 60% of patients,
fatigue is common, and nausea and/or vomiting affects 30% of
patients but is readily controlled with antiemetics. Less common
side effects include constipation, headaches, conjunctivitis,
anorexia, abdominal pain, hair thinning, ankle swelling, and chest
pain due to coronary vasospasm (Van Cutsem et al. 2002). The
use of capecitabine in patients with impaired renal function
should be cautious, requiring a 25% dose reduction for those 
with a creatinine clearance of 30–49 mL/min and should 
be discontinued if the clearance falls significantly during 
therapy until recovery occurs. Patients may receive the drug
safely despite markedly abnormal liver function since
capecitabine does not undergo significant hepatic metabolism
(Schüll et al. 2003) but administration in such cases should 
be cautious as such patients are likely to have advanced 
disease and a poor performance status with little prospect of an
effective benefit.
When capecitabine is used in combination, such as with
gemcitabine, the dose-limiting toxicity is myelosuppression and
thus the dose of capecitabine needs to be attenuated to allow
full-dose gemcitabine to be delivered (Schilsky et al. 2002). The
result is a reduction in the incidence of diarrhea and hand-foot
syndrome in combination schedules such as in the UK GemCap
trial where the incidence of grade 3/4 hand-foot syndrome was
2%, grade 3/4 diarrhea was 1%, and serious stomatitis was not a
problem (Cunningham et al. 2005).
Economic evidence
There are as yet no studies that include an economic evaluation
of capecitabine in pancreatic cancer. However, studies have been
undertaken in colorectal cancer comparing oral capecitabine with
intravenous fluorouracil delivered using either bolus or infusional
schedules (Ward et al. 2003; Cassidy et al. 2006). The data show
that while drug acquisition costs are somewhat higher for
capecitabine, the costs of managing toxicity are broadly similar
and the cost of delivering capecitabine is significantly less than
that of fluorouracil due to considerable savings in pharmacy and
chemotherapy nursing resources. In addition, the use of
capecitabine allows considerable reduction in patient travel costs,
and time spent in hospital. Overall, when compared with
fluorouracil, capecitabine results in 57% lower chemotherapy-
related costs and is therefore a cost-effective option when used
as a single agent in colon cancer. In pancreatic cancer the
addition of capecitabine to gemcitabine adds little in terms of
administration costs, and with reduced capecitabine toxicity in
combination regimens, minimal additional resources are needed
to manage side effects. The main additional costs therefore relate
to drug acquisition, and individual health economies must decide
whether or not the modest increase in survival justifies this outlay.
Patient group/population
Performance status is the most important determinant of
likelihood of response to chemotherapy in the common solid
tumors and pancreatic cancer is no exception. This was
highlighted in the SAKK/CECOG study outlined above where a
subgroup analysis showed a significantly improved median
survival with capecitabine for patients with KPS ≥90% (Herrmann
et al. 2005). Thus patients with few symptoms and a World Health
Organization performance status of 0–1 are more likely to benefit
from palliative chemotherapy and to tolerate treatment without
undue toxicity. Patients with a performance status of 3 are most
unlikely to benefit, and for these patients chemotherapy
frequently results in unacceptable toxicity. A performance status
of 2 tends to encompass quite a broad spectrum with some
patients being reasonably fit and well enough for a trial of
chemotherapy while others, closer to a performance status of 3,
are best served by best supportive care. 
Clinical potential
Capecitabine (Xeloda) is an oral prodrug which is converted to
fluorouracil by three sequential enzymatic reactions (Tabata et al.
2004). The final requisite enzyme, thymidine phosphorylase, is
present at consistently higher levels in tumors compared with
normal tissues (Miwa et al. 1998; Nakayama et al. 2005), thereby
suggesting that fluorouracil delivered in this way may benefit from
an element of tumor targeting and thus enhanced selectivity and
better tolerability (Ishikawa et al. 1998; Schüller et al. 2000).
Fluorouracil is known to be most effective when administered as
a protracted infusion but such schedules require indwelling
catheters and in pancreatic cancer these cause particular
problems with venous thromboembolism. Capecitabine may
therefore represent an attractive option since continuous daily
dosing can mimic a protracted venous infusion and avoids the
need for central lines. Capecitabine has been shown to have
modest single-agent activity in advanced carcinoma of the
pancreas and when used in combination with gemcitabine may
Capecitabine | outcomes review
Core Evidence 2007;2(2)provide a small but significant improvement in response rates and
survival compared with gemcitabine alone. These advantages
may be most marked in patients with a good performance status
and it is in this group where combination treatment including
capecitabine is most likely to be of value.
Publication of the final results of both the SAKK/CECOG
(Herrmann et al. 2005) and GemCap phase III (Cunningham et al.
2005) trials in advanced pancreatic cancer are needed before
more certain conclusions can be drawn as to the role of
capecitabine in conjunction with gemcitabine in advanced
pancreatic cancer.
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